Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses

Braz J Psychiatry. 2021 Sep-Oct;43(5):462-464. doi: 10.1590/1516-4446-2020-0024.

Rodrigo Machado-Vieira^{1

2}, João Quevedo^{2

3

4

5}, Lokesh Shahani², Jair C Soares^{1

2

4}

¹ Experimental Therapeutics and Molecular Pathophysiology Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.
² Center of Excellence in Mood Disorders, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth, Houston, TX, USA.
³ Translational Psychiatry Program, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, UTHealth, Houston, TX, USA.
⁴ Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center, UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
⁵ Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), Criciúma, SC, Brazil.

No abstract available

Publication types